Repros Therapeutics Company Profile (NASDAQ:RPRX)

About Repros Therapeutics (NASDAQ:RPRX)

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:RPRX
  • CUSIP: 76028H20
  • Web: www.reprosrx.com
Capitalization:
  • Market Cap: $9.89 million
  • Outstanding Shares: 26,732,000
Average Prices:
  • 50 Day Moving Avg: $0.44
  • 200 Day Moving Avg: $0.94
  • 52 Week Range: $0.30 - $2.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.37
  • P/E Growth: -0.010
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.06 per share
  • Price / Book: 6.07
Profitability:
  • EBIDTA: ($18,370,000.00)
  • Net Margins: -49,564.86%
  • Return on Equity: -276.50%
  • Return on Assets: -195.41%
Debt:
  • Current Ratio: 1.57%
  • Quick Ratio: 1.57%
Misc:
  • Average Volume: 719,649 shs.
  • Beta: 0.56
  • Short Ratio: 2.05
 

Frequently Asked Questions for Repros Therapeutics (NASDAQ:RPRX)

What is Repros Therapeutics' stock symbol?

Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."

How were Repros Therapeutics' earnings last quarter?

Repros Therapeutics Inc. (NASDAQ:RPRX) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.08. The firm had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative return on equity of 276.50% and a negative net margin of 49,564.86%. View Repros Therapeutics' Earnings History.

Where is Repros Therapeutics' stock going? Where will Repros Therapeutics' stock price be in 2017?

2 equities research analysts have issued 12-month price objectives for Repros Therapeutics' stock. Their predictions range from $1.50 to $1.50. On average, they expect Repros Therapeutics' stock price to reach $1.50 in the next twelve months. View Analyst Ratings for Repros Therapeutics.

Are investors shorting Repros Therapeutics?

Repros Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totalling 1,790,958 shares, an increase of 165.8% from the June 15th total of 673,714 shares. Based on an average daily trading volume, of 1,094,710 shares, the short-interest ratio is presently 1.6 days. Currently, 6.2% of the shares of the stock are sold short.

Who are some of Repros Therapeutics' key competitors?

Who are Repros Therapeutics' key executives?

Repros Therapeutics' management team includes the folowing people:

  • Patrick P. Fourteau, Chairman of the Board
  • Larry M. Dillaha M.D., President, Chief Executive Officer, Director
  • Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary
  • Joachim F. Wernicke, Chief Medical Officer
  • Daniel F. Cain, Independent Director
  • Nola E. Masterson, Independent Director
  • Saira Ramasastry, Independent Director
  • Michael G. Wyllie Ph.D., Independent Director

How do I buy Repros Therapeutics stock?

Shares of Repros Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repros Therapeutics' stock price today?

One share of Repros Therapeutics stock can currently be purchased for approximately $0.37.


MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $1.50 (305.30% upside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017LaidlawDowngradeBuy -> NeutralMediumView Rating Details
1/30/2017S&P Equity ResearchBoost Price Target$1.22 -> $1.50N/AView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesUpgradeNeutral -> BuyN/AView Rating Details
2/9/2016Piper Jaffray CompaniesReiterated RatingNeutralN/AView Rating Details
12/4/2015Brean CapitalReiterated RatingHoldN/AView Rating Details
10/30/2015Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Repros Therapeutics (NASDAQ:RPRX)
Earnings by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Earnings History by Quarter for Repros Therapeutics (NASDAQ RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.15)($0.22)$0.01 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.17)($0.16)$0.01 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.18)($0.17)$0.01 millionViewN/AView Earnings Details
8/9/2016Q216($0.20)($0.18)$0.02 millionViewN/AView Earnings Details
5/10/2016Q1($0.22)($0.20)$0.02 millionViewN/AView Earnings Details
3/14/2016Q4($0.27)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
Current Year EPS Consensus Estimate: $-1.0700 EPS
Next Year EPS Consensus Estimate: $-1.0100 EPS

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Repros Therapeutics (NASDAQ:RPRX)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 21.71%
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Institutional Ownership by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Joseph PodolskiInsiderBuy20,000$1.60$32,000.00View SEC Filing  
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Repros Therapeutics (NASDAQ:RPRX)
Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
Source:
DateHeadline
americanbankingnews.com logoRepros Therapeutics Inc. (RPRX) Lowered to "Neutral" at Laidlaw
www.americanbankingnews.com - July 21 at 9:30 AM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 7:23 AM
finance.yahoo.com logoRepros' Proellex Stays on Partial Clinical Hold, Shares Fall
finance.yahoo.com - July 19 at 7:22 AM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.
finance.yahoo.com - July 17 at 8:33 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
finance.yahoo.com - July 17 at 3:31 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)
finance.yahoo.com - July 17 at 3:31 PM
streetinsider.com logoRepros Therapeutics (RPRX) Reports Proellex Development Program to Remain on Partial Clinical Hold by the FDA - StreetInsider.com
www.streetinsider.com - July 17 at 8:11 AM
finance.yahoo.com logoRepros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
finance.yahoo.com - July 17 at 8:11 AM
americanbankingnews.com logoRepros Therapeutics Inc. (RPRX) Short Interest Up 165.8% in June
www.americanbankingnews.com - July 16 at 7:14 AM
americanbankingnews.com logoRepros Therapeutics Inc. (RPRX) Short Interest Update
www.americanbankingnews.com - June 13 at 7:14 AM
globenewswire.com logoRepros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock - GlobeNewswire (press release)
globenewswire.com - May 18 at 10:57 AM
streetinsider.com logoRepros Therapeutics (RPRX) Plans Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - May 18 at 10:57 AM
finance.yahoo.com logoRepros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
finance.yahoo.com - May 18 at 10:57 AM
streetinsider.com logoRepros Therapeutics (RPRX) Plans Offering of Common Stock, Warrants
www.streetinsider.com - May 17 at 7:32 PM
finance.yahoo.com logoRepros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
finance.yahoo.com - May 17 at 7:32 PM
globenewswire.com logoRepros Therapeutics Inc.® Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 10 at 7:50 PM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - May 10 at 6:40 PM
finance.yahoo.com logoRepros Therapeutics Inc.® Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 7:07 PM
marketbeat.com logoRepros Therapeutics reports 1Q loss
marketbeat.com - May 9 at 5:44 PM
nasdaq.com logoWhat's in the Cards for Repros (RPRX) this Earnings Season? - Nasdaq
www.nasdaq.com - May 6 at 12:55 AM
zacks.com logoWhat's in the Cards for Repros (RPRX) this Earnings Season?
www.zacks.com - May 5 at 7:54 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Stock Price
www.americanbankingnews.com - May 4 at 2:26 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Given Daily News Impact Score of 0.04
www.americanbankingnews.com - May 1 at 3:26 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Receives Daily News Impact Rating of 0.26
www.americanbankingnews.com - April 28 at 4:38 PM
americanbankingnews.com logoPositive Media Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Share Price
www.americanbankingnews.com - April 24 at 3:26 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Earning Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 21 at 6:09 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Share Price
www.americanbankingnews.com - April 17 at 7:25 PM
finance.yahoo.com logoRepros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
finance.yahoo.com - April 17 at 6:40 PM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Short Interest Up 0.0% in March
www.americanbankingnews.com - April 13 at 4:50 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Receiving Somewhat Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 12:26 PM
finance.yahoo.com logoRepros' Proellex Continues to be Under Partial Clinical Hold
finance.yahoo.com - April 11 at 7:24 PM
zacks.com logoRepros' Proellex Continues to be Under Partial Clinical Hold
www.zacks.com - April 11 at 9:58 AM
finance.yahoo.com logoWoodlands drug company names new top exec
finance.yahoo.com - April 11 at 9:58 AM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as CEO
www.streetinsider.com - April 10 at 7:06 PM
finance.yahoo.com logoRepros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids drug
finance.yahoo.com - April 10 at 7:06 PM
seekingalpha.com logoFDA continues partial clinical hold for Repros Therapeutics' fibroids drug
seekingalpha.com - April 10 at 10:22 AM
finance.yahoo.com logoCompany Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids
finance.yahoo.com - April 10 at 9:23 AM
finance.yahoo.com logoRepros Names Larry Dillaha, M.D., its Permanent President and CEO
finance.yahoo.com - April 10 at 9:23 AM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Announces Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - April 3 at 7:32 AM
us.rd.yahoo.com logoRepros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 31 at 7:46 PM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 31 at 7:46 PM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 11 at 12:42 AM
nasdaq.com logoRepros (RPRX) Q4 Earnings: What's in Store for the Stock? - Nasdaq
www.nasdaq.com - March 8 at 7:52 PM
finance.yahoo.com logoRepros (RPRX) Q4 Earnings: What's in Store for the Stock?
finance.yahoo.com - March 7 at 7:29 PM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - February 8 at 11:34 PM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO - StreetInsider.com
www.streetinsider.com - February 4 at 7:41 PM
bizjournals.com logoCEO leaves Woodlands-based drug company; interim named
www.bizjournals.com - February 3 at 11:38 PM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO
www.streetinsider.com - February 3 at 3:10 AM
us.rd.yahoo.com logo9:16 am Repros Therapeutics President and CEO Joseph S. Podolski is leaving his position to pursue other interests; Larry Dillaha, M.D., CEO of CavtheRx, was appointed interim President and CEO, effective immediately
us.rd.yahoo.com - February 3 at 3:10 AM
streetinsider.com logoRepros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex
www.streetinsider.com - February 1 at 3:11 AM

Social

Chart

Repros Therapeutics (RPRX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff